Myomo (MYO)
(Delayed Data from AMEX)
$3.83 USD
+0.27 (7.58%)
Updated May 10, 2024 04:00 PM ET
After-Market: $3.84 +0.01 (0.26%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Price, Consensus and EPS Surprise
MYO 3.83 +0.27(7.58%)
Will MYO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MYO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYO
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
What Makes Myomo, Inc. (MYO) a Good Fit for 'Trend Investing'
MYO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Myomo, Inc. (MYO) Reports Q2 Loss, Tops Revenue Estimates
Myomo's (MYO) MyoPro Seeks CMS Classification for Medicare Cover
Here's Why Myomo, Inc. (MYO) Is a Great 'Buy the Bottom' Stock Now
Other News for MYO
Myomo Inc (MYO) Q1 2024 Earnings Call Transcript Highlights: Navigating Growth Amid Financial ...
Myomo’s Strategic Turnaround: A Buy Rating with Revenue Growth and Operational Scaling on the Horizon
Myomo Inc Reports Q1 2024 Earnings: Revenue Up Despite Challenges
Myomo price target raised by 50c at Alliance Global Partners, here's why
Myomo’s Strong Growth Potential Amid New CMS Guidelines Elicits a Buy Rating